We are developing a versatile CMOS-integrated biosensor platform for rapid genomic identification. Quicksilver Biosciences is a venture capital backed biotech startup based in NYC. Utilizing proprietary sensing techniques, Quicksilver aims to achieve target sensitivities exceeding current state-of-the-art, while doing so in a portable form-factor and at reduced cost.
New York, United States
Founded in 2018
1-10 Employees
Working industry
Biotechnology
Type of company
-
Ownership structure
Privately Held
Locations
1 Headquarter
Specialised areas
Biotechnology
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
United States
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
D
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
A
Grade (A-E)
View details
Quicksilver Biosciences operates in 1 country around the world
Get an overview of the locations of Quicksilver Biosciences
Location
Country
State
City
Headquarter
United States
New York
New York
Some frequent questions that have been asked about Quicksilver Biosciences
Where is Quicksilver Biosciences located?
The company headquarter of Quicksilver Biosciences is located in New York, New York, United States. It's worth noting, that the company may have more locations
How many employees does Quicksilver Biosciences approximately have?
As of the latest available information Quicksilver Biosciences has around 1-10 employees worldwide.
When was Quicksilver Biosciences founded?
Quicksilver Biosciences was founded in 2018
In which industries does Quicksilver Biosciences mainly work?
The company Quicksilver Biosciences has it's main focus in the industries of Biotechnology
Check out some interesting alternative companies to Quicksilver Biosciences
Quick Biology Inc.
Pasadena, United States
1-10 Employees
2015
We are specialized in developing new technologies to allow scientists/physicians to obtain more results in less time. Quick Biology is a startup biotechnology company located in Pasadena, CA.
Invitrometrix
Lowell, United States
1-10 Employees
2016
Our vision is to improve and accelerate research by providing repeatability of experiments with quantitative culture health measurements and set acceptable parameters to determine if the experiment should proceed. We are pleased to announce our first basic research device, the Discovery-Q! We are providing the pharmaceutical and research industries with a multi-well whole-cell biosensor. Invitrometrix designs and manufactures a multi-well Quartz Crystal Microbalance (QCM), a sensitive surface sensing technology. We are pleased to announce our first commercial device the Discovery-Q. Our Discovery-Q is a platform that changes that! Using our commercial Discovery-Q in research offers sensitivity, consistency and significant reduction in sample manipulation resulting in more meaningful and consistent results. The Discovery-Q is a non-invasive, label free approach, generating a continuous flow of real-time data.
Q Bio
San Carlos, United States
11-50 Employees
2015
We are a technology company operating at the intersection of AI, Physics and Biology to automate the physical exam from data collection to triage and routing to make preventive personalized healthcare available to everyone. Q Bio’s HQ is in sunny San Carlos, CA. We are a multidisciplinary team from a variety of backgrounds, all with the determination to succeed together. We are accountable to each other, committed to collaboration, and seek to inspire one another. At Q Bio, we believe assumptions are made to be broken. Q Bio is developing three technology pillars that will ultimately be vertically integrated and combined with commodity vitals & biochemistry collection to enable Digital Twins and Large Biological Model-powered personalized health forecasts at population scale. Quantitative, generates reproducible data optimized for machine interpretation. We are piloting the Gemini Exam under a research protocol at our site in Redwood City, with more availability to come via Gemini Platform partners.
Quantum SI
Guilford, United States
51-100 Employees
2013
Quantum-Si’s Next Generation Protein Sequencing Technology Enables Rapid and Accurate Distinction of Variants of the SARS-CoV-2 Virus. Quantum-Si and Researchers to Highlight the Power of Next-Generation Protein Sequencing™ on Platinum® at US HUPO Conference. Quantum-Si Reports Fourth Quarter and Full Year 2023 Financial Results. Detecting single amino acids through binding kinetics, the innovative Platinum® benchtop sequencer is highly sensitive to protein variants, enabling deep interrogation of proteins to deliver breakthrough insights.
Quantum Silicon
Edmonton, Canada
1-10 Employees
2011
At QSi we develop the world's first practical implementation of field controlled computing. We develop, manufacture, and license high-speed, all-silicon electronics to meet the semiconductor industry's need for products that are faster and dramatically more energy efficient. The result is a new generation of quantum accelerators that are tiny, fast, and cool. Now, over 30 years later, QSi is leading the world in developing and using atomically precise manufacturing to create electronics that use no transistors, are far faster than their transistor-based equivalent, and consume orders of magnitude less energy. As the development of atom scale devices transitions from novel, proof-of-concept demonstrations to state-of-the-art commercial applications, automated assembly of such devices must be implemented. By training the network to differentiate between common defects we are able to avoid charged defects as well as edges of the patterning terraces. We additionally incorporated this molecular repassivation technique as the primary rewriting mechanism in ultradense atomic data storage designs (0.88 petabits per in2). With nanoelectronics reaching the limit of atom-sized devices, it has become critical to examine how irregularities in the local environment can affect device functionality.
SiPhox
Cambridge, United States
11-50 Employees
2020
Our mission is to enable new Direct-to-Consumer health and wellness paradigms to address this crisis. We are convinced that everyone will be wearing silicon photonic chips in the future to continuously monitor health biomarkers. We are bringing a next-generation optical chip-based biosensor to market. The reason we are doing this is to drive demand and leverage that to drive our costs down. Our goal is to eventually make it possible to test all these markers in the home instantly at a 10x lower cost. SiPhox’s interdisciplinary team merges biochemistry and photonic chip technology to deliver more biomarker data, faster, and with less blood volume. SiPhox was founded by Diedrik Vermeulen and Michael Dubrovsky one month BC (before Covid) in 2020. SiPhox’s technology enables a next-generation biosensing platform that provides the power a large laboratory instruments in a handheld device that accepts disposable cartridges.